Application Nr Approved Date Route Status External Links
NDA017681 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications Hiprex Is Indicated For Prophylactic Or Suppressive Treatment Of Frequently Recurring Urinary Tract Infections When Long-Term Therapy Is Considered Necessary. This Drug Should Only Be Used After Eradication Of The Infection By Other Appropriate Antimicrobial Agents. To Reduce The Development Of Drug-Resistant Bacteria And Maintain The Effectiveness Of Hiprex And Other Antibacterial Drugs, Hiprex Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Susceptible Bacteria. When Culture And Susceptibility Information Are Available, They Should Be Considered In Selecting Or Modifying Antibacterial Therapy. In The Absence Of Such Data, Local Epidemiology And Susceptibility Patterns May Contribute To The Empiric Selection Of Therapy.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Methenamine Hippurate METHENAMINE HIPPURATE ZINC86040406

Comments